Biocon, Asia’s premier biotechnology company, has made clinical progress in its partnered programs with Mylan. The partnership has a strong portfolio of generic insulin analogs and biosimilars including Monoclonal Antibodies (MAbs) and recombinant proteins at various stages of development.
Two molecules Pegfilgrastim (PEG-G-CSF) and Adalimumab have entered global Phase 3 clinical trials. While the PEG-G-CSF trial is well underway the Adalimumab trial has been recently initiated. In addition, the Phase 3 global clinical trial for Trastuzumab is progressing in more than 100 sites around the world. An initial ROW focused Phase 3 trial for Bevacizumab is also underway.
Further, two global clinical trials for generic Insulin Glargine initiated in 2014, have also made significant progress. The patient recruitment for Type-1 diabetes study has been completed ahead of schedule, while the recruitment for Type-2 diabetes study is expected to be completed by July 2015.
Biocon is India’s largest and Asia’s leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
